GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

116 calculators match

Most used

21
MELD-NaAssesses the severity of chronic liver diseaseChild-Pugh ScoreAssesses the prognosis of chronic liver disease, mainly cirrhosisFIB-4 IndexLiver fibrosis scoring indexAPRIAST to platelet ratio — liver fibrosisMaddrey's DFAlcoholic hepatitis severityGlasgow-BlatchfordUpper GI bleed risk stratificationGAHSGlasgow alcoholic hepatitis scoreMontreal IBDIBD classification — CD & UCMayo ScoreUlcerative colitis activityBISAP ScoreBedside index for severity of pancreatitisCLIF-SOFAOrgan failure scoring in cirrhosisAlcohol ContentStandard drinks & alcohol grams calculatorAARC-ACLFAcute-on-chronic liver failure gradePELD / CR ScorePediatric end-stage liver diseaseHarvey-BradshawCrohn's disease activity indexCTSICT severity index — pancreatitisRockall ScoreGI bleed rebleeding & mortality riskCAGEAlcohol use disorder screening (4 questions)MELD 3.0Updated MELD — sex-inclusive formulaAUDIT ScoreAlcohol use disorders identification testVOCAL-Penn ScorePost-operative mortality risk in cirrhosis surgery

Liver & Cirrhosis

17
ALBI GradeAlbumin-bilirubin liver function grade in HCCUKELD ScoreUK model for end-stage liver diseaseMELD-XIMELD excluding INR — for anticoagulated patientsWest Haven CriteriaHepatic encephalopathy gradingMilan CriteriaLiver transplant eligibility in hepatocellular carcinomaLI-RADS v2018 (CT/MRI)Liver observation category from size, APHE and major featuresBCLC StagingHepatocellular carcinoma stage and treatment allocationSimplified AIH CriteriaSimplified criteria for autoimmune hepatitisRevised Original AIH ScoreIAIHG 1999 comprehensive autoimmune hepatitis scoreSAAGSerum-ascites albumin gradient — cause of ascitesR FactorHepatocellular vs cholestatic pattern in liver injuryCLIF-C ACLFMortality prediction in acute-on-chronic liver failureKing's College CriteriaTransplant criteria in acute liver failureGALAD ScoreHCC detection from gender, age, AFP-L3, AFP and DCPMetroticket 2.0AFP-adjusted up-to-seven for HCC transplant eligibilityRUCAMCausality in drug- and herb-induced liver injuryBaveno VII CriteriacACLD, CSPH and sparing screening endoscopy

Fibrosis & MASLD

8
NAFLD Fibrosis ScoreAdvanced fibrosis probability in MASLD/NAFLDBARD ScoreBMI, AST/ALT ratio, diabetes — MASLD fibrosisFatty Liver IndexPredicts hepatic steatosis from routine labsFibrotic NASH Index (FNI)At-risk NASH probability from AST, HbA1c and HDLNAFLD Activity Score (NAS)Histologic activity grade — steatosis, inflammation, ballooningMEFIB IndexMRE + FIB-4 rule for significant fibrosis (≥F2) in MASLDFAST ScoreFibroScan-AST — at-risk NASH from LSM, CAP and ASTSAFE ScoreSteatosis-Associated Fibrosis Estimator for MASLD in primary care

Pancreas & Biliary

8
Ranson's CriteriaAcute pancreatitis severity at 48 hoursGlasgow-Imrie CriteriaAcute pancreatitis severity — the PANCREAS criteriaHAPSHarmless acute pancreatitis scoreTokyo Guidelines — CholangitisTG18 diagnosis and severity grade for acute cholangitisTokyo Guidelines — CholecystitisTG18 diagnosis and severity grade for acute cholecystitisBiliary Pain (Rome IV)Rome IV — defining biliary-type pain before interventionFunctional Pancreatic SODRome IV — pancreatic sphincter of Oddi disorderRevised Atlanta ClassificationAcute pancreatitis severity — mild, moderately severe, severe

IBD

9
Truelove & Witts CriteriaAcute severe ulcerative colitis — admission decisionUCEISUlcerative colitis endoscopic index of severitySCCAISimple clinical colitis activity index — symptoms onlyCDAICrohn's disease activity index — the trial standardSES-CDEndoscopic severity in Crohn's diseasePUCAIPaediatric ulcerative colitis activity indexTravis (Oxford) CriteriaDay 3 colectomy risk in acute severe ulcerative colitisHo IndexDay 3 steroid failure risk in acute severe ulcerative colitisRutgeerts ScorePostoperative Crohn's recurrence at ileocolonoscopy

GI Bleeding

7
EVendo ScorePredicts oesophageal varices needing treatmentForrest ClassificationPeptic ulcer bleeding — rebleeding risk at endoscopyAIMS65 ScoreUpper GI bleed mortality — five bedside criteriaOakland ScoreSafe-discharge risk for acute lower GI bleedingABC ScoreAge, blood tests, comorbidities — GI bleed mortalitySarin ClassificationEndoscopic classification of gastric varicesEGUS (Gastric Ulcer)Malignancy risk in a gastric ulcer, and who needs repeat endoscopy

Alcohol

2
ABIC ScoreAge, bilirubin, INR, creatinine — alcoholic hepatitisLille ModelSteroid response at day 7 in alcoholic hepatitis

Upper GI

4
Chicago Classification v4.0Oesophageal motility pattern from high-resolution manometryLA Classification (Oesophagitis)Los Angeles grade A–D for erosive oesophagitisPrague C & M CriteriaCircumferential and maximal extent of Barrett's oesophagusEREFS (Eosinophilic Oesophagitis)Endoscopic reference score — oedema, rings, exudates, furrows, stricture

Colorectal

3
Boston Bowel Prep ScaleColonoscopy preparation adequacy by segmentStool Osmotic GapOsmotic vs secretory diarrhoea from stool electrolytesATLAS Score (C. difficile)Predicted response to therapy in Clostridioides difficile infection

Functional GI

37
Bristol Stool ScaleStool form types 1–7 and colonic transitRome IV Criteria for IBSIrritable bowel syndrome diagnosis and subtypeFunctional ConstipationRome IV — two of six items, IBS excludedOpioid-Induced ConstipationRome IV — constipation tied to opioid therapyFunctional DiarrhoeaRome IV — loose stools without predominant painFunctional Bloating / DistensionRome IV — bloating without other bowel disorder criteriaUnspecified Functional Bowel DisorderRome IV — bowel symptoms fitting no other categoryCentrally Mediated Abdominal Pain (CAPS)Rome IV — continuous pain unrelated to gut eventsNarcotic Bowel SyndromeRome IV — opioid-induced hyperalgesia of the gutFaecal Incontinence (Rome IV)Rome IV — the criteria, and why nobody is askedFunctional Anorectal PainLevator ani, unspecified pain and proctalgia fugaxFunctional Defecation DisordersRome IV — dyssynergia and inadequate propulsionInfant RegurgitationRome IV — the happy spitter, and the alarm features that rule it outInfant ColicRome IV — recurrent unexplained crying in a well infant under 5 monthsInfant DyscheziaRome IV — straining before a soft stool, and why not to intervenePaediatric Functional ConstipationRome IV — two of six over one month, with overflow soiling as a criterionToddler's DiarrhoeaRome IV functional diarrhoea of childhood — painless, thriving childPaediatric Cyclic Vomiting SyndromeRome IV — both age bands, with different criteria for eachPaediatric Rumination SyndromeRome IV — infant and child/adolescent criteriaFunctional Nausea & Vomiting (Children)Rome IV — two separate disorders that can be met togetherAerophagiaRome IV — distension that increases through the dayPaediatric Functional DyspepsiaRome IV — four times a month, with PDS and EPS subtypingPaediatric Irritable Bowel SyndromeRome IV — plus the constipation clause clinicians missAbdominal MigraineRome IV — stereotypical incapacitating episodes weeks apartFunctional Abdominal Pain — NOSRome IV — the residual category, reached after the other threeNonretentive Faecal IncontinenceRome IV — soiling without retention, where laxatives make it worseFunctional DyspepsiaRome IV — with PDS and EPS subtypingRumination SyndromeRome IV — effortless regurgitation without retchingCyclic Vomiting SyndromeRome IV — stereotypical episodic vomitingCannabinoid HyperemesisRome IV — CVS pattern relieved by cannabis cessationChronic Nausea & VomitingRome IV — chronic nausea and vomiting syndromeBelching DisordersRome IV — supragastric vs gastric belchingFunctional HeartburnRome IV — heartburn with normal acid exposureReflux HypersensitivityRome IV — normal acid exposure, positive symptom associationFunctional Chest PainRome IV — non-cardiac, non-reflux chest painGlobusRome IV — painless lump-in-throat sensationFunctional DysphagiaRome IV — dysphagia with normal endoscopy and manometry
  1. Calculators
  2. /
  3. Functional Dyspepsia
Functional GI

Functional Dyspepsia

Rome IV — with PDS and EPS subtyping

B1. Functional dyspepsia

Upper endoscopy is named explicitly in the criteria. Coeliac serology and, where prevalence warrants it, Helicobacter pylori testing are the other routine investigations expected before this is answered yes.

B1a. Postprandial distress syndrome

One or both, at least 3 days a week.

Note the definition: not simply feeling full sooner, but full enough that a normal meal cannot be finished.

B1b. Epigastric pain syndrome

One or both, at least 1 day a week.

Epigastric burning, not retrosternal burning. Heartburn is not a dyspeptic symptom under Rome IV, though it frequently coexists.

Two steps. Functional dyspepsia requires at least one of four cardinal symptoms plus no structural disease — and the patient must then also fulfil postprandial distress syndrome, epigastric pain syndrome, or both. The two subtypes carry different frequency thresholds and frequently coexist.

When to use
Use it in a patient with chronic upper abdominal symptoms centred on the epigastrium once upper endoscopy is normal. The criteria are most useful for the subtyping, which is where the treatment decision actually sits — the two subtypes respond to different first-line therapy, and a diagnosis of 'functional dyspepsia' without a subtype leaves the most actionable information on the table. It does not apply to a patient with alarm features, to one who has not had endoscopy where endoscopy is indicated, or to heartburn, which Rome IV explicitly does not count as a dyspeptic symptom even though it coexists constantly.
Why use it
Because dyspepsia is one of the highest-volume presentations in gastroenterology and the default pathway — a proton pump inhibitor, then another endoscopy, then another proton pump inhibitor — serves it badly. Rome IV's contribution is the subtype split: postprandial distress syndrome is a meal-related disorder associated with impaired gastric accommodation, while epigastric pain syndrome is a pain disorder that may have nothing to do with eating at all. Those respond differently, and prescribing acid suppression to a patient whose symptom is early satiation after meals is a common and predictable failure. The criteria also enforce something the pathway often omits: a positive diagnosis, given as an explanation, in a condition where patients are routinely told only what they do not have.
Formula, evidence and interpretation

About the Rome IV Criteria for Functional Dyspepsia (PDS and EPS)

Two steps, and the second is the one people skip. Functional dyspepsia requires at least one of four cardinal symptoms — bothersome postprandial fullness, early satiation, epigastric pain or epigastric burning — with no structural disease including at upper endoscopy, over three months with onset at least six months ago. But Rome IV then requires the patient to fulfil a subtype as well: postprandial distress syndrome, whose items must occur at least three days a week, or epigastric pain syndrome, whose items need only one day a week. Meeting the general criteria without meeting a subtype does not make the diagnosis.

On this page

  • Formula
  • Interpreting the result
  • Inputs
  • What it returns
  • How it is calculated
  • Facts & figures
  • Evidence
  • How it compares
  • Pearls & pitfalls
  • Critical actions
  • Why it exists
  • About the creator
  • Limitations
  • If you are the patient
  • FAQ
  • Related calculators
  • References

Formula

Functional dyspepsia = timing AND no structural disease AND (PDS OR EPS) PDS = postprandial fullness OR early satiation, ≥ 3 days/week EPS = epigastric pain OR epigastric burning, ≥ 1 day/week
PDS threshold
Three days a week for either item. The higher bar reflects that postprandial fullness is a very common experience and needs a frequency threshold to become pathological.
EPS threshold
One day a week for either item. Pain is treated as more inherently abnormal than fullness, so the threshold is lower.
Overlap
A patient can fulfil both subtypes simultaneously, and Rome IV allows it. Overlap predicts more severe symptoms and poorer treatment response than either subtype alone.
  • The two-step structure is the commonest source of error. Meeting the general criteria without hitting a subtype frequency is not functional dyspepsia under Rome IV.
  • The subtype frequency thresholds differ — 3 days a week for PDS items, 1 day a week for EPS items — and applying one to the other misclassifies patients.
  • Heartburn is explicitly not a dyspeptic symptom, though Rome IV notes it may often coexist. Reflux disease and functional dyspepsia frequently overlap.
  • Symptoms relieved by passing stool or gas should generally not be counted as dyspepsia — that pattern points toward irritable bowel syndrome.
  • Persistent vomiting suggests another disorder and should prompt reconsideration rather than being absorbed into a dyspepsia label.
  • Rome IV drops the older requirement that pain be related to meals. Pain while fasting counts.

Interpreting the result

Read the subtype, because it is where the treatment decision lives. Epigastric pain syndrome is the subtype most likely to respond to acid suppression, and a proton pump inhibitor trial is a reasonable first move. Postprandial distress syndrome responds less well to acid suppression and better to prokinetics and to practical dietary advice — smaller, lower-fat, more frequent meals — which costs nothing and is frequently not given. In both subtypes, test for Helicobacter pylori and treat if positive: eradication produces sustained relief in a minority of patients, that minority cannot be identified in advance, and Rome IV regards a patient whose symptoms resolve after eradication as having had H. pylori-associated dyspepsia rather than the functional disorder. Where first-line treatment fails, the evidence-based next step is a neuromodulator at low dose, not a repeat endoscopy. Overlap between the subtypes is common and predicts a harder course. Finally, expect coexistence with irritable bowel syndrome and with reflux disease — Rome IV explicitly permits it, and treating one while ignoring the others is a frequent reason management appears to fail.

ScoreBandWhat it meansAction
PDS onlyPostprandial distress syndromeMeal-related fullness or early satiation at least 3 days a week; associated with impaired gastric accommodationDietary advice on smaller, lower-fat meals; consider a prokinetic. Acid suppression performs less well in this subtype
EPS onlyEpigastric pain syndromeEpigastric pain or burning at least 1 day a week, which may be meal-induced, meal-relieved or occur fastingA proton pump inhibitor trial is reasonable first-line; test and treat Helicobacter pylori
Both subtypesPDS and EPS overlapBoth symptom clusters at their required frequencies. Predicts more severe symptoms and poorer treatment responseExpect a harder course; move to a neuromodulator earlier rather than cycling through single-agent trials
Any requirement unmetCriteria not metMost often because no subtype reaches its frequency threshold, despite the general criteria being satisfiedCheck the subtype thresholds specifically — 3 days a week for PDS items, 1 day a week for EPS items

What the Functional Dyspepsia needs (6 inputs)

Timing
Criteria fulfilled for the last three months with symptom onset at least six months before diagnosis. Unlike the oesophageal disorders, the overall frequency requirement sits in the subtypes rather than in the general criteria.
No structural, organic, systemic or metabolic disease, including at upper endoscopy
Upper endoscopy is named explicitly. Coeliac serology and, in populations where prevalence justifies it, Helicobacter pylori testing are the other routine investigations expected before this is answered affirmatively.
PDS — bothersome postprandial fullness, at least 3 days a week
Bothersome means severe enough to impact usual activities. The frequency threshold for the PDS items is three days a week, three times stricter than for the EPS items.
PDS — bothersome early satiation, at least 3 days a week
Rome IV defines this precisely: severe enough to prevent finishing a regular-size meal. Feeling full sooner than usual does not qualify; being unable to finish does.
EPS — bothersome epigastric pain, at least 1 day a week
Pain may be induced by eating, relieved by eating, or occur while fasting. Rome IV is deliberately agnostic about the meal relationship here, which is a change in emphasis from earlier frameworks.
EPS — bothersome epigastric burning, at least 1 day a week
Epigastric burning, not retrosternal burning. Heartburn is not a dyspeptic symptom under Rome IV, and the criteria note it may often coexist without becoming part of the diagnosis.

What it returns

Criteria met or not met
Requires the timing rule, the exclusion of structural disease, and fulfilment of at least one subtype.
Subtype — PDS, EPS, or overlap
Reported explicitly, including overlap. This is the output that determines first-line treatment, and overlap is common enough that collapsing it to a single subtype loses information.

How it is calculated

The subtype division rests on a mechanistic claim: that meal-related and pain-related dyspepsia are different disorders that happen to share an anatomical region. Postprandial distress syndrome is associated with impaired accommodation of the proximal stomach and with hypersensitivity to gastric distension — the stomach fails to relax normally to receive a meal, so a normal volume produces fullness. Epigastric pain syndrome tracks more closely with duodenal hypersensitivity, low-grade duodenal inflammation and eosinophilia, and altered central pain processing. Rome IV set different frequency thresholds for the two because the underlying symptoms have different base rates: postprandial fullness is near-universal at low frequency, whereas bothersome epigastric pain is not. The structure is otherwise conjunctive, and the exclusion of structural disease does the same work it does in every Rome IV disorder.

Facts & figures

The two subtypes side by side
Postprandial distress syndromeEpigastric pain syndrome
SymptomsPostprandial fullness; early satiationEpigastric pain; epigastric burning
Frequency thresholdAt least 3 days a weekAt least 1 day a week
Relationship to mealsMeal-related by definitionMay be induced by, relieved by, or independent of meals
Associated mechanismImpaired gastric accommodation; hypersensitivity to distensionDuodenal hypersensitivity and low-grade inflammation; central pain processing
First-line treatmentDietary modification; prokineticsProton pump inhibitor trial

The differing frequency thresholds are the detail most often applied wrongly. Using the 1-day-a-week bar for postprandial fullness over-diagnoses PDS substantially.

What Rome IV says does NOT belong to dyspepsia
SymptomRome IV position
HeartburnNot a dyspeptic symptom, though it may often coexist
Symptoms relieved by passing stool or gasShould generally not be considered part of dyspepsia — suggests IBS
Persistent vomitingLikely suggests another disorder
Bloating, belching, nauseaSupportive features that can be present, but do not themselves satisfy any criterion

The supportive features are the trap in the other direction: a patient with bloating, belching and nausea but none of the four cardinal symptoms at threshold does not have functional dyspepsia by Rome IV.

Evidence

Derivation — Rome Foundation, gastroduodenal disorders committee

2016

Consensus criteria produced by the Rome IV gastroduodenal disorders committee and published in Gastroenterology in 2016, revising Rome III. Developed by expert committee with systematic literature review rather than fitted to a cohort.

The substantive changes from Rome III were the addition of explicit frequency thresholds to the subtypes — three days a week for PDS, one for EPS — and the requirement that symptoms be 'bothersome', defined as severe enough to impact usual activities.

Guideline adoption — ACG and CAG 2017

2017

Joint clinical guideline of the American College of Gastroenterology and the Canadian Association of Gastroenterology on the management of dyspepsia.

Recommends test-and-treat for Helicobacter pylori in patients without alarm features, endoscopy in those aged 60 and over, and sets out the evidence for proton pump inhibitors, prokinetics and neuromodulators in functional dyspepsia.

Overlap with other disorders

2016

Rome IV explicitly permits coexistence of functional dyspepsia with gastro-oesophageal reflux disease and with irritable bowel syndrome, listing this among the supportive criteria for both subtypes.

Overlap is common rather than exceptional, and Rome IV's position is that the presence of one does not exclude the others — a departure from the tidier but less accurate mutual exclusivity applied to the oesophageal disorders.

How it compares

Functional Dyspepsia vs Gastroparesis

Overlapping symptoms and a blurred boundary — a gastric emptying study separates them on paper, but the distinction predicts treatment response less well than it should.

Gastroparesis is defined by delayed gastric emptying with compatible symptoms, and postprandial distress syndrome shares nearly all of those symptoms. In practice the two populations overlap heavily: emptying is delayed in a proportion of patients meeting PDS criteria, patients labelled gastroparetic frequently have normal emptying on repeat testing, and emptying rate correlates poorly with symptom severity. The practical position is that the gastric emptying study is worth doing where the answer would change management — particularly before considering gastroparesis-specific therapies — but that a normal study does not invalidate the patient's symptoms and an abnormal one does not explain them fully.

Functional Dyspepsia vs Rome IV criteria for IBS

Not mutually exclusive — Rome IV explicitly permits coexistence, and the overlap is common enough that assuming one diagnosis excludes the other is a frequent error.

Functional dyspepsia and irritable bowel syndrome coexist in a substantial proportion of patients, and Rome IV lists this among the supportive criteria for both dyspepsia subtypes. The distinguishing question is what relieves the symptom: dyspeptic symptoms are not relieved by passing stool or gas, whereas that relationship is central to IBS. A patient with epigastric pain relieved by defecation is being described by the IBS criteria, not the dyspepsia ones. Where both are present, both need treating — a patient given a proton pump inhibitor for dyspepsia while their bowel symptoms go unaddressed will usually report that nothing has helped.

Open the Rome IV criteria for IBS calculator →

Functional Dyspepsia vs Helicobacter pylori-associated dyspepsia

A separate entity in Rome IV rather than a subtype — if eradication produces sustained relief, the diagnosis was H. pylori-associated dyspepsia and not the functional disorder.

This distinction is definitional and can only be made retrospectively. Rome IV's position is that a patient whose dyspeptic symptoms resolve durably after successful eradication did not have functional dyspepsia, which is why test-and-treat belongs before the functional label rather than after it. The proportion who respond is a minority, and no clinical feature identifies them in advance, so the only way to find them is to test and treat everyone who is positive. The ACG and CAG guideline builds this into the recommended pathway for patients without alarm features.

Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112(7):988-1013.

Pearls & pitfalls

  • The diagnosis is two-stage. Meeting the general criteria is not enough — the patient must also fulfil PDS or EPS at its own frequency threshold, and this is the most common scoring error.
  • The subtype thresholds differ: 3 days a week for postprandial fullness and early satiation, 1 day a week for epigastric pain and burning. Applying one to the other misclassifies.
  • Early satiation has a precise definition — severe enough to prevent finishing a regular-size meal. Feeling full sooner is not the same thing.
  • Heartburn is not a dyspeptic symptom under Rome IV, however often it coexists. A patient whose dominant symptom is heartburn is being assessed for the wrong disorder.
  • Symptoms relieved by passing stool or gas point to irritable bowel syndrome and generally should not be counted as dyspepsia.
  • Rome IV dropped the requirement that epigastric pain be meal-related. Pain while fasting counts, which widens EPS relative to older frameworks.
  • Persistent vomiting is not part of this disorder and should prompt reconsideration rather than being absorbed into the label.
  • Test for Helicobacter pylori before settling on the functional diagnosis — a patient whose symptoms resolve after eradication had H. pylori-associated dyspepsia, which Rome IV treats as a separate entity.
  • Overlap with IBS and with reflux disease is explicitly permitted and is common. Treating one and ignoring the others is a frequent reason management appears to fail.
  • Bloating, belching and nausea are supportive features only. None of them satisfies a criterion on its own.

Critical actions

  • Establish the subtype explicitly, with its frequency, rather than recording 'functional dyspepsia' alone — the subtype is what determines first-line treatment.
  • Perform upper endoscopy where indicated, and check coeliac serology; the criteria require structural, organic, systemic and metabolic disease to be excluded on routine investigation.
  • Test for Helicobacter pylori and treat if positive, before concluding the disorder is functional.
  • Screen for alarm features — weight loss, dysphagia, persistent vomiting, gastrointestinal bleeding, a mass, iron deficiency anaemia, or new onset over 60 — none of which belongs to this diagnosis.
  • In PDS, give practical dietary advice on smaller, lower-fat, more frequent meals; it is effective, free, and routinely omitted.
  • In EPS, trial a proton pump inhibitor first-line and stop it if it does not work rather than continuing indefinitely.
  • Where first-line treatment fails, move to a low-dose neuromodulator rather than repeating endoscopy.
  • Ask about bowel symptoms and about reflux, since overlap is common and each needs addressing on its own terms.

Why this score exists

The committee's most consequential decision was to make the subtypes mandatory rather than descriptive. Under Rome III, subtyping was available but a patient could carry a functional dyspepsia label without one; Rome IV requires fulfilment of PDS or EPS, which forces the clinician to establish which symptom cluster is present and at what frequency. The stated reasoning was that the two subtypes have different pathophysiology and different treatment responses, so a diagnosis that does not distinguish them is not clinically actionable. The addition of 'bothersome' as a defined term — severe enough to impact usual activities — was the other significant change, made because the previous criteria captured large numbers of people with symptoms they did not regard as a problem. Both changes narrow the diagnosis, and the committee accepted that as the price of a category that means something.

About the creator

  • Vincenzo Stanghellini

    First author, Rome IV gastroduodenal disorders committee

    Chaired the committee that wrote the Rome IV criteria for the functional gastroduodenal disorders.

  • Jan Tack

    Co-author; gastric accommodation and dyspepsia subtyping

    Contributed much of the underlying work on impaired gastric accommodation that the PDS subtype rests on.

  • Nicholas J. Talley

    Co-author; duodenal eosinophilia and dyspepsia epidemiology

    Co-authored the chapter and contributed the work on duodenal inflammation associated with the epigastric pain subtype.

Limitations

  • Entirely symptom-based, with no biomarker, so the diagnosis depends on the accuracy of the history and on the patient and clinician sharing a definition of fullness, satiation and burning.
  • The subtype split, while mechanistically motivated, does not predict treatment response as cleanly as the criteria imply, and overlap is common.
  • The frequency thresholds are consensus judgements rather than empirically derived cut-points.
  • 'Bothersome' requires a subjective judgement of impact on usual activities, which varies between patients and cultures.
  • The boundary with gastroparesis is blurred, and gastric emptying correlates poorly with symptoms in both directions.
  • Requires upper endoscopy, which is not universally available and is not always indicated in younger patients without alarm features — leaving the exclusion criterion partly unverifiable in primary care.
  • Does not address the substantial psychological comorbidity that accompanies functional dyspepsia and predicts a worse course.
  • Says nothing about severity beyond the binary of bothersome or not, so a patient meeting criteria may be mildly or severely affected.

If you are the patient

Functional dyspepsia means ongoing discomfort in the upper abdomen — fullness after eating, feeling full very quickly, or pain or burning just below the breastbone — when a camera test has shown no ulcer, inflammation or other physical cause. It is common and it is real; the problem is in how the stomach and its nerves are working rather than in its structure. Doctors divide it into two types, and which one you have changes the treatment. If your main problem is feeling uncomfortably full after meals or not being able to finish a normal-sized meal, that is the meal-related type, and smaller, lower-fat, more frequent meals genuinely help, sometimes alongside a medicine that helps the stomach empty. If your main problem is pain or burning in the upper abdomen, that is the pain type, and acid-reducing tablets are more likely to work. Many people have both. Two things are worth asking about. First, whether you have been tested for a stomach bacterium called Helicobacter pylori — treating it clears the symptoms completely in some people, and there is no way to tell in advance who. Second, whether your bowels are also affected, because irritable bowel syndrome often occurs alongside this and needs treating in its own right; people frequently feel nothing is working when in fact only half the problem is being treated.

Frequently asked questions

What are the Rome IV criteria for functional dyspepsia?#

One or more of bothersome postprandial fullness, early satiation, epigastric pain or epigastric burning, with no evidence of structural disease including at upper endoscopy, fulfilled for three months with onset at least six months earlier. The patient must additionally fulfil postprandial distress syndrome or epigastric pain syndrome — meeting the general criteria alone is not sufficient.

What is the difference between PDS and EPS?#

Postprandial distress syndrome is meal-related — bothersome postprandial fullness or early satiation, at least three days a week. Epigastric pain syndrome is pain-related — bothersome epigastric pain or burning, at least one day a week, which may be induced by eating, relieved by eating, or occur while fasting. The frequency thresholds differ, and so does first-line treatment.

Why do PDS and EPS have different frequency thresholds?#

Because the underlying symptoms have different base rates. Postprandial fullness is a near-universal experience at low frequency, so it needs a higher bar — three days a week — before it becomes pathological. Bothersome epigastric pain is less common in the general population, so one day a week is sufficient. Applying the wrong threshold to the wrong subtype is the most common misapplication of these criteria.

Can you have both PDS and EPS?#

Yes, and it is common. Rome IV permits fulfilment of both subtypes simultaneously. Overlap predicts more severe symptoms and a poorer response to treatment than either subtype alone, which is a reason to move to a neuromodulator earlier rather than cycling through single-agent trials.

Is heartburn a symptom of functional dyspepsia?#

No. Rome IV states explicitly that heartburn is not a dyspeptic symptom, though it notes that it may often coexist. A patient whose dominant complaint is retrosternal burning is being assessed for reflux disease, functional heartburn or reflux hypersensitivity rather than for dyspepsia — although reflux disease and functional dyspepsia frequently overlap and both may need treating.

Do you need an endoscopy to diagnose functional dyspepsia?#

The criteria require no evidence of structural disease 'including at upper endoscopy', so endoscopy is expected. In practice, guidelines recommend a test-and-treat approach for Helicobacter pylori in younger patients without alarm features and reserve endoscopy for those aged 60 and over or with alarm features. Where endoscopy has not been done, the diagnosis is provisional.

How is functional dyspepsia treated?#

Test and treat Helicobacter pylori first. Then by subtype: a proton pump inhibitor trial for epigastric pain syndrome, and dietary modification with smaller, lower-fat meals plus consideration of a prokinetic for postprandial distress syndrome. Where first-line treatment fails, a low-dose neuromodulator is the evidence-based next step — not a repeat endoscopy.

What is the difference between functional dyspepsia and gastroparesis?#

Gastroparesis requires delayed gastric emptying on formal testing; functional dyspepsia does not. In practice the two overlap heavily — emptying is delayed in a proportion of patients meeting PDS criteria, and emptying rate correlates poorly with symptom severity in both directions. A gastric emptying study is worth doing where the result would change management, but a normal study does not invalidate the symptoms.

Can functional dyspepsia and IBS occur together?#

Yes, and Rome IV explicitly permits it, listing coexistence among the supportive criteria for both dyspepsia subtypes. The discriminating feature is that dyspeptic symptoms are not relieved by passing stool or gas. Where both disorders are present, both need treating — addressing only one is a common reason patients report that nothing has helped.

Related calculators

  • Rome IV Criteria for IBS — Irritable bowel syndrome diagnosis and subtype
  • Chronic Nausea & Vomiting — Rome IV — chronic nausea and vomiting syndrome
  • Rumination Syndrome — Rome IV — effortless regurgitation without retching
  • Belching Disorders — Rome IV — supragastric vs gastric belching
  • Functional Heartburn — Rome IV — heartburn with normal acid exposure

References

Original / primary reference

  1. Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, Talley NJ. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-1392 (Rome IV).

Clinical practice guidelines

  1. Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112(7):988-1013.

Other references

  1. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393-1407 (the IBS criteria dyspepsia overlaps with).

Last updated July 31, 2026. Clinical knowledge base written and curated by GastroAGI Team from primary medical literature.

Written from primary literature and not yet independently clinically reviewed.

For use by qualified healthcare professionals. This calculator supports clinical judgement and does not replace it.